KemPharm Q3 net loss widens to $0.19/shr; cash $107.4M, runway into 2026

ZEVRA THERAPEUTICS, INC.

Net loss of $6.6M ($0.19/share) vs loss of $1.8M ($0.05) in Q3 2021; revenue $2.9M (+45% YoY).
R&D expense $5.4M (up from $2.2M) on KP1077 and arimoclomol programs; G&A $4.0M (up from $1.9M).
Cash and investments $107.4M as of Sep 30, 2022; based on current forecast, runway extends into 2026.
Arimoclomol NDA resubmission for NPC expected as early as Q3 2023; ongoing FDA discussions.
KP1077 Phase 2 trial in IH to initiate by year-end 2022; Phase 1 CV safety trial completed.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ZEVRA THERAPEUTICS, INC. reported the third quarter ended September 30, 2022 results: revenue $2.9 million, net income ($6.6) million, or ($0.19) per basic and diluted share.

Period: the third quarter ended September 30, 2022
Revenue: $2.9 million
Net income: ($6.6) million, or ($0.19) per basic and diluted share
Result: reported results

Exact text from the filing

strategy could provide further capital flexibility and extend the operating cash runway. Overview of Third Quarter 2022 Financial Results: Net revenue for Q3 2022 was $2.9 million, as compared to Q3 2021 net revenue of $2.0 million. The period-over-period increase was primarily attributed to revenue from the arimoclomol Early Access Program (EAP) in

View on SEC.gov

Browse all earnings releases →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-026611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.